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As with albumin, small tri and tetra peptides are poor mod-
els for the metal binding properties of hepcidin.
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Introduction
Hepcidin is a peptide hormone secreted by the liver in 
response to iron loading and inflammation [1], it controls 
the export of iron from duodenal epithelial cells, hepato-
cytes and macrophages and consequently influences the 
level of serum iron available for the bone marrow and other 
tissues heavily dependent on iron supply [2–6]. There are 
more than 200 entries of hepcidin sequences in SwissProt. 
Some of the common species are shown in Table 1 together 
with the conservation of the sequence (Table 1).
Interestingly, the N-terminal region of human hepcidin 
is capable of binding CuII and NiII ions via an ATCUN 
(amino-terminal Cu-Ni)-binding motif comprising the three 
N-terminal residues (H2N-XXH) [7, 8]. In principle almost 
all hepcidin molecules can chelate CuII at the N-terminal 
region, as the majority possess the ATCUN motif, the 
exceptions amongst the most common sequences, being rat 
and mouse where position 3 is occupied by asparagine; tial-
pia, where position 3 is arginine and bass where, although 
position 3 is serine and position 1 is histidine. Thus even 
those sequences lacking the ATCUN motif are predicted to 
bind CuII. Several research groups have demonstrated the 
binding of transition metals to hepcidin, for instance Far-
naud et al. [9] reported the binding of FeII and Balesaria 
et al. [10] reported that the regulation of hepcidin levels is 
influenced not only by FeII, but also ZnII, CdII and CuII. In 
view of this interest in the divalent metal binding properties 
Abstract Hepcidin is a peptide hormone that regu-
lates the homeostasis of iron metabolism. The N-terminal 
domain of hepcidin is conserved amongst a range of spe-
cies and is capable of binding CuII and NiII through the 
amino terminal copper–nickel binding motif (ATCUN). It 
has been suggested that the binding of copper to hepcidin 
may have biological relevance. In this study we have inves-
tigated the binding of CuII with model peptides containing 
the ATCUN motif, fluorescently labelled hepcidin and hep-
cidin using MALDI-TOF mass spectrometry. As with albu-
min, it was found that tetrapeptide models of hepcidin pos-
sessed a higher affinity for CuII than that of native hepcidin. 
The log K1 value of hepcidin for Cu
II was determined as 
7.7. CuII binds to albumin more tightly than hepcidin (log 
K1 = 12) and in view of the serum concentration difference 
of albumin and hepcidin, the bulk of kinetically labile CuII 
present in blood will be bound to albumin. It is estimated 
that the concentration of CuII-hepcidin will be less than one 
femtomolar in normal serum and thus the binding of copper 
to hepcidin is unlikely to play a role in iron homeostasis. 
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of hepcidin, particularly the binding of CuII, we decided to 
investigate this interaction and to quantify the affinity con-
stant of hepcidin for CuII, such that we could compare the 
affinity constant with other endogenous CuII binding pro-
teins and in particular albumin.
Human serum albumin (HSA), the most abundant pro-
tein of blood serum, participates in blood CuII transport 
[11]. The N-terminal three amino acid residues for human 
serum albumin are Asp-Ala-His; the ATCUN motif. On 
the basis of studies centred on tri- and tetrapeptide mim-
ics of the N-terminus of human albumin it has been sug-
gested that CuII is bound in a slightly distorted square pla-
nar geometry by four nitrogen’s in the equatorial plane: the 
aspartate amino group, two deprotonated amide functions 
from the first two peptide bonds and the Nπ nitrogen of the 
imidazole side chain of the histidine residue (Fig. 1a) [12].
In principle the structure of the CuII complex of human 
hepcidin could adopt a similar structure, as previously sug-
gested by Tselepis et al. [8] (Fig. 1b) who reported the dis-
sociation constant between hepcidin and CuII as ≪1 µmol/L 
[8]. As CuII is a kinetically labile cation [13], both human 
albumin and human hepcidin might be expected to compete 
with each other. In view of this possibility it is important 
to establish an accurate affinity constant for the binding 
of CuII to hepcidin. For this reason we have monitored the 
binding of CuII to human hepcidin, fluorescent human hep-
cidin and three peptide models of the N-terminus of human 
hepcidin, in order to gain a better insight into the possible 
significance of this potentially important CuII-hepcidin 
interaction.
Materials and methods
Materials
All solutions were prepared with Milli-Q (18 MQ) water. 
The Fmoc amino acid derivatives were obtained from 
Bachem AG (4416 Bubendorf, Switzerland). DMF, DMSO, 
3-(N-morpholino) propanesulfonic acid (MOPS), copper 
atomic standard solution, acetonitrile, nitrilotriacetic acid 
(NTA), potassium chloride, Cu(II) sulphate pentahydrate 
and other reagents were purchased from Sigma-Aldrich 
and used without further purification. Analytical grade vol-
umetric hydrochloric acid (0.2092 mol/L) and HPLC grade 
water (Fisher) were used in the preparation of all solutions 
used for potentiometry.
Table 1  Alignment and conservation of some hepcidin sequences
DTH FP I C I FC CGCC- - HRSK CGMCCKT
DTH FP I Y I FC CGCC- - HRSK CGMCCKT
DTH FP I C I FC CGCC- - HRSK CGMCCKT
DTH FP I C I FC CGCC- - HRSK CGMCCRT
DTH FP I C I FC CGCC- - HRSK CGMCCRT
DTH FP I C I FC CGCC- - RQSN CGMCCKT
DTH FP I C I FC CGCC- - RQSN CGMCCKT
DTH FP I C I FC CGCC- - RKA I CGMCCKT
DTH FP I C I FC CGCC- - KT PK CGLCCKT
DTH FP I C I FC CGCC- - YK SK CG I CCKT
DTH FP I C I FC CGCC- - YP SK CG I CCKT
DTH FP I C I FC CGCC- - RKGT CGMCCRT
DTH FP I C I FC CGCC- - RKGT CG I CCKT
DTH FP I CV FC CGCC- - KNAR CG I CCKT
DTN FP I C I FC CKCC- - NN SQ CG I CCKT
DTN FP I C L FC CKCC- - KN SS CGLCC I T
D I N FP I CR FC CQCC- - NK P S CG I CCEE
QSH L SLCRFC CKCC- - RNKG CGYCCK F
Q I H L SLCGLC CNCC- - HN I G CGFCCK F
QGSPARCRFC CRCC- PRMRG CG I CCRF
H SSPGGCRFC CNCC- PNMSG CGVCCRF
HKRG I KCRFC CGCCT PG I - - CGVCCRF
QSH L S I CVHC CNCC- - K YKG CGKCC L T
Fig. 1  Structure of 
[CuII(DAHK)] and complex 
[CuII(DTH)] complexes. 
a X-ray structure of the 
[CuII(DAHK)] complex. The 
CuII ion is penta-coordinated 
with four nitrogen ligands in 
equatorial positions (N1 to N4) 
and one water molecule in the 
apical position (O8) [12]. b 
Energy minimized structure for 
[CuII(DTH-NH2)] complex
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Peptide synthesis
In the hepcidin sequence (DTHFPICIFCCGCCHRSKCG-
MCCKT) Methionine 21 was replaced with a Lysine 
(M21K) which was protected on the ε-amino group with 
the (4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl group 
(Dde). Peptide synthesis was carried out on a CEM Liberty 
1 microwave peptide synthesizer with Fmoc-Thr(tBu)-
Trt-Resin on a 0.2 mmol scale. All deprotection reactions 
were carried out with 20 % piperidine in dimethylforma-
mide (v/v). Acylation reactions were carried out using 
2-(6-chloro-1-H-benzotriazole-1-yl)1,1,3,3-tetrameth-
ylaminiumhexafluorophosphate (HCTU) (0.78 mmol) 
in the presence of 2,4,6-collidine (1.6 mmol) for 10 min 
using 25 W microwave power. Cysteine and histidine 
were activated with diisopropylcarbodiimide (0.8 mmol) 
and ethyl cyano(hydroxylimino) acetate (0.8 mmol). Boc-
Asp(OtBu)-OH was incorporated at the N-terminus [14]. 
Peptides DTH, GGHG and DTHFPIAIF-NH2 were pre-
pared similarly on PEG-PS resin.
For the preparation of the labelled hepcidin, the peptide 
resin (400 mg, 69 μmol) was treated with 15 mL of hydra-
zine hydrate in dimethylformamide (2 %, v/v) to selec-
tively remove the Dde group. The free amino group was 
acylated with either dichloro-6-carboxyfluorescein (65 mg, 
173 μmol) or 6-carboxy tetramethylrhodamine (45 mg, 
104 μmol), diisopropylcarbodiimide (27 μL, 173 μmol) 
and ethyl cyano(hydroxyimino) acetate (25 mg, 173 μmol) 
in 2 mL of DMF over 18 h.
The peptide resins were cleaved from the solid support 
and simultaneously deprotected using trifluoroacetic acid, 
phenol, water, thioanisole and 3,6-dioxo-1,8-octanedithiol 
(82.5/5/5/0.5/2.5) for 4 h and precipitated in diethyl ether 
and then freeze dried.
The linear labelled hepcidin was then dissolved in 
reducing buffer (100 mL) composed of tris hydrochloride 
(0.5 mol/L), EDTA (0.1 mmol/L) and guanidine hydro-
chloride (6 mol/L) at pH 8.0 and reduced with excess 
dithiothreitol (53 mg, 345 μmol). The fluorescent pep-
tide solution was acidified to pH 2.5 and then purified by 
preparative HPLC on a Vydac 218TP54 peptide and pro-
tein column (2.5 × 30 cm). The folding buffer (6.8 L) was 
composed of ammonium bicarbonate (100 mmol/L), EDTA 
(0.1 mmol/L), guanidine hydrochloride (2 mol/L), reduced 
glutathione (2.10 g, 6.9 mmol) and oxidized glutathione 
(0.42 g, 0.69 mmol). The purified reduced peptide was dis-
solved in folding buffer (100 ml) containing 6 mol/L Gdm-
HCl and added to the bulk of the folding buffer. The solu-
tion was stirred for 48 h and the solution was purified by 
preparative HPLC to produce the crude folded peptide.
All peptides were purified by preparative HPLC on a 
Vydac peptide and protein column 218 TP54 semiprepara-
tive column (1.0 × 30 cm) and the resulting fractions were 
analysed on a Jupiter HPLC column (5 µm, C18, 300 Å, 
2 mm × 150 mm, Phenomenex) using a 1100 HPLC sys-
tem (Agilent Technologies). Mass spectrometry analy-
sis of the peptides was carried out using matrix-assisted 
laser desorption ionization on a Bruker Autoflex [15]. An 
Nd:YAG laser (355 nm) was used to irradiate the sample. 
The instrument was calibrated with a range of peptides 
covering the mass range (500–4000 Da). Samples were 
prepared on an Anchor Chip® with a saturated solution of 
α-cyano-4-hydroxy-cinnamic acid as the matrix in a mix-
ture of acetonitrile and 0.1 % trifluoroacetic acid. Direct 
infusion experiments were carried out on a linear Ion Trap 
(Thermo). (S1,S8: S3,S6: S2,S4: S5,S7-tetracyclo-DTHF-
PICIFCCGCCHRSKCGMCCKT (Hepcidin), S1,S8: S3,S6: 
S2,S4: S5,S7-tetracyclo-DTHFPICIFCCGCCHRSKCGK(5-
tetramethylrhodamine)CCKT (M12K-TMR-hepcidin) and 
S1,S8: S3,S6: S2,S4; S5,S7-tetracyclo-DTHFPICIFCCGCCHR 
SKCGK(Dichloro-5-carboxyfluoresceine)CCKT (M21K-
dichloro-CF-Hepcidin) were successfully prepared. Both 
M21K-TMR-hepcidin and M21K-dichloro-CF hepcidin 
exhibited measurable potency when tested in cultured 
Madin-Darby canine kidney (MDCK) and T47D cell 
expressing ferroportin [16].
Potentiometric titration
The potentiometric titration system used in the study of 
GGHG, GGH and DTH-NH2 and their Cu
II complexes 
comprised of an autoburette (Metrohm Dosimat 765 litre 
mL syringe) and Mettler Toledo MP230 pH meter with 
Metrohm pH electrode (6.0133.100) and a reference elec-
trode (6.0733.100). A potassium chloride electrolyte solu-
tion (100 mmol/L) was used to maintain the ionic strength. 
The temperature of the test solutions was maintained in 
a thermostatic jacketed titration vessel at 25 ± 0.1 °C by 
using a Techne TE-8 J temperature controller. The solu-
tion under investigation was stirred vigorously during the 
experiment. All instruments were interfaced to a computer 
and controlled by a Visual Basic program. An automated 
titration adopted the following strategy: the pH of a solu-
tion was increased by 0.1 pH unit by the addition of potas-
sium hydroxide solution (100 mmol/L) from the autobu-
rette; when pH readings varied by <0.01 pH unit over a 
8 s period, they were judged to be stable and an incuba-
tion period was activated. For pKa determinations, an incu-
bation period of 1.5 min was adopted; for metal stability 
constant determinations, an incubation period of 3 min was 
adopted. The cycle was repeated automatically until the 
defined end point pH value was achieved. All the titration 
data were analysed with the pHab program [17]. The spe-
cies plot was calculated with the HYSS program [17, 18]. 
Analytical grade reagent materials were used in the prepa-
ration of all solutions.
 J Biol Inorg Chem
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Spectrophotometric titration
Following the same procedure as described in 2.3, the spec-
trum of the solution was additionally recorded at the end 
of the incubation period. The test solution was circulated 
through a Hellem quartz flow cuvette by a Gilson Mini-
plus #3 pump with speed capability (20 mL/min). The flow 
cuvette was mounted on an HP 8453 UV–visible spectro-
photometer. For pKa determinations, a cuvette path length 
of 10 mm was used while for metal stability constant deter-
minations, a cuvette path length of 50 mm was used.
Fluorescence spectroscopy
Fluorescence spectra were obtained using a Perkin Elmer 
LS50B fluorometer. Excitation and emission frequencies 
of 552 and 576 nm were adopted, and data were recorded 
at room temperature. Briefly, sample volumes of 2 ml, 
with peptide concentrations of 0.5 µmol/L M21K-TMR-
hepcidin in 0.25 mol/L MOPS buffer (pH 7.45)/acetoni-
trile (v/v = 50:50) and aqueous 2 µmol/L CuIISO4 solution 
(50 µl) was added every 5 min.
Mass spectrometry
The peptides were dissolved in a standard copper solution 
to form a 1:1 peptide to copper preparation. The solution 
was serially diluted with 20 mmol/L ammonium bicar-
bonate to prepare peptide—CuII solutions of different 
concentrations.
For the preparation of the liquid matrix for MALDI-
MS, 10 mg of α-cyano-4-hydroxycinnamic acid, 30 μL of 
diisopropylethylamine and 50 μL of 10 mmol/L ammo-
nium phosphate in aqueous methanol (50 %) were vortexed 
and sonicated to obtain a solution. This solution was then 
diluted 30-fold with 20 mmol/L ammonium bicarbonate: 
methanol (1:1, v/v). The sample and the matrix (2 μL 
each) were mixed and then spotted onto a MALDI plate 
and allowed to evaporate to yield a liquid film. The samples 
were then analysed by MALDI-TOF.
Results
In order to gain a better understanding of CuII binding by 
the ACTUN motif of hepcidin we have studied CuII binding 
to various hepcidin N-terminal peptides. Some are tri- and 
tetrapeptides and are limited to the ACTUN motif and one 
DTHFPIAIF-NH2, is a nonapeptide representing the N-ter-
minal section of hepcidin with the cysteine being replaced 
by alanine. We have also studied CuII binding to human 
hepcidin and two fluorescently labelled human hepcidin 
analogues.
Synthesis of the peptides
The synthesis of the peptides proceeded without any major 
difficulties the percentage yields of the crude peptides 
GGHG, DTH-NH2 and DTHFPIAIF-NH2 were 20, 40 and 
60 % respectively. All peptides were greater than 95 % pure 
as demonstrated by HPLC and corresponded to the correct 
structures as confirmed by electrospray ionization mass 
spectrometry (ESI–MS) and/or MALDI-TOF MS data. For 
the labelled peptides, the linear peptides were successfully 
synthesised on the solid support by replacing methionine21 
with Lys(Dde), the Dde group was removed with hydrazine 
and the free amino group was labelled with either 6-car-
boxytetramethylrhodamine or 6-carboxy dichloro-carboxy-
fluoresceine. The peptide was cleaved from the solid sup-
port, purified and then folded under oxidative conditions 
containing oxidised and reduced glutathione to produce the 
products, which were characterised by HPLC and MALDI-
TOF MS (see supplementary data). Both M21K-TMR-hep-
cidin and M21K-dichloro-CF hepcidin exhibited measur-
able potency when tested in cultured Madin-Darby canine 
kidney (MDCK) and T47D cell expressing ferroportin [16].
Potentiometric determination of the pKa values 
of GGHG and DTH‑NH2
The potentiometric titration and resulting speciation plot 
for GGHG are presented in Fig. 2a. The pKa values are 8.1 
(terminal amino group), 6.7 (imidazole group) and 3.2 (car-
boxy function) (Table 2).
The predominant form at pH 7.4 is AH where the ter-
minal amino group function remains protonated and the 
peptide lacks a net charge. The pH titration and resulting 
speciation plot for DTH-NH2 are presented in Fig. 2c. The 
pKa values are 7.9 (terminal amino group), 6.3 (imidazole 
group) and 2.8 (carboxy function) (Table 2). The predomi-
nant form at pH 7.4 is AH where the terminal amino group 
function remains protonated and the peptide lacks a net 
charge.
Spectrophotometric determination of CuII affinity 
constants for GGHG and DTH‑NH2
GGHG, spectrophotometric titration in the presence 
of CuIISO4 resulted in the formation of a complex 
(λmax = 528 nm) (Fig. 3a) from which the conditional 
affinity constant at pH 7.4 was determined, namely log 
K1 = 12.84. With DTH-NH2, titration with CuIISO4 
resulted in the formation of a complex (λmax = 530 nm) 
(Fig. 3b) from which the conditional affinity constant at pH 
7.4 was determined as log K1 = 12.93.
These values are close to the reported CuII log conditional 
affinity constants for some analogous peptides, that correspond 
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to the N-terminal sequence of human albumin (DAH), for 
instance DAHK-NH2 (13.8) [19] and DAH-NH2 (13.7) [20]. It 
is significant that these two values are higher than the log con-
ditional affinity constant for CuII and HSA [21].
In order to further investigate the interaction of CuII with 
this peptide class we measured the log conditional affinity 
constants for GGH in order to compare the values deter-
mined in this study with the values previously reported for 
this tripeptide [22, 23] and with the values for GGHG (this 
study) and GGHGG [22]. The values are all in good agree-
ment with each other despite differing experimental condi-
tions being adopted in the three laboratories (Table 3).
Fig. 2  The potentiometric titration of GGHG and DTH-NH2. a Potentiometric titration of 16.5 mg GGHG with 0.1 M KOH. b The speciation 
plot of GGHG. c Potentiometric titration of DTH-NH2. 16.6 mg with 0.1 M KOH. d The speciation plot of DTH-NH2
Table 2  Stability constants of short peptides
* pCuII7.4 under condition [ligand]Total = 10−5 M, [CuII]Total = 10−6 M, 
pH = 7.4
Species GGHG DTH-NH2 GGH
LH 8.1 7.9 8.3
LH2 6.7 6.3 6.8
LH3 3.2 2.8 2.6
CuIILH 3.7 3.3 2.4
CuIILH2 −1.1 −1.4 −1.6
logK7.4 12.8 12.9 12.2
pCuII7.4* 13.8 13.9 13.1
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In this investigation, we adopted spectrophotometric 
titration over the pH range 2.5–10.5, whereas in previous 
studies, data of the potentiometric titration over the pH 
range 2.0–7.8 was adopted [22, 23]. With both GGH and 
GGHG we observed a transition over the pH range 6.5–8.5 
which was possibly not recorded by the previous workers. 
We attribute this transition to the formation of copper com-
plex dimers as previously suggested by Aiba et al. [24].
Determination of the copper(II) affinity constants 
for fluorescently labelled hepcidin
We selected two fluorescently labelled hepcidins which 
were both derivitised on position-21, a residue believed 
to be orientated away from the ferroportin binding region 
of hepcidin. This is somewhat confirmed by both these 
Fig. 3  Spectrophotometric 
titration spectra of GGHG and 
DTH-NH2 with Cu
II. a Titra-
tion spectra of GGHG with 
CuII, [GGHG] = 2.33 mmol/L 
and [CuII] = 1.11 mmol/L, 
ratio of L:M = 2.1, start-
ing in 21.741 mL 0.1 M KCl 
at 25 °C, pH 2.267 to pH 
10.030. b Titration spec-
tra of DTH-NH2 with Cu
II, 
[DTH-NH2] = 2.94 mmol/L 
[CuII] = 735.5 µmol/L, ratio of 
L:M = 4, starting in 20.667 ml 
0.1 M KCl at 25 °C, pH 1.814 
to pH 9.207
Table 3  CuII Log conditional affinity constants at pH 7.4
Peptide LogK1 References
GGH 12.4 [23]
GGH 12.3 [22]
GGH 12.2 This work
GGHG 13.6 [22]
GGHG 13.13 This work
J Biol Inorg Chem 
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molecules possessing biological activity [16]. Unfortu-
nately both the labelled hepcidin molecules possess a low 
solubility in water, although they are soluble in aqueous 
acetonitrile mixtures. Initially a CuII titration was under-
taken with M21K-TMR-hepcidin in 50 % aqueous acetoni-
trile. Copper was found to quench the fluorescence in a 
dose dependent manner (Fig. 4). This titration yielded a log 
conditional affinity constant of M21K-TMR-hepcidin for 
CuII (log K1) of 7.5. The quenching studies were repeated at 
20, 40, 60 and 70 % aqueous acetonitrile, which rendered it 
possible to extrapolate the resulting logK1 values for Cu
II 
to aqueous solution (see supplementary data). The extrap-
olated value was determined as logK1 = 7.22. Thus there 
was acceptable agreement between the two determined CuII 
affinity constants, but both were found to be much lower 
than the affinity constants determined for the N-terminal 
segments of hepcidin, namely logK1 in the range 12.2–
13.6. It is significant to note that there is a similar differ-
ence between the affinities of CuII of short N-terminal pep-
tides of albumin and albumin itself [19, 21].
The difference in this behaviour is likely to be related 
to the relative ease of the formation of a square planar CuII 
structure, involving the dissociation of two amide protons. 
Small restrictions in the geometry could lead to relatively 
large changes in the affinity constant. By analogy with albu-
min, it is likely that the higher value of Log K1 (Cu
II) for 
the N-terminal peptides, when compared with fluorescently 
labelled hepcidins, results from an interaction of the ATCUN 
motif with the rest of the hepcidin structure. Indeed the C-ter-
minal region of hepcidin is close to the N-terminus region 
in the native structure it being held in such a position by the 
numerous disulphide bonds present in the structure [6].
Determination of hepcidin copper(II) affinity constants 
by mass spectroscopy
Although the two fluorescently labelled hepcidin molecules 
are likely to interact with CuII in a similar fashion to that 
of the native molecule, the possibility exists that the fluo-
rescent probe could interfere with the conformation of the 
N-terminus region. Consequently we studied the binding 
of CuII to a N-terminal model peptide of hepcidin (DTHF-
PIAIF-NH2) and human hepcidin by MALDI-TOF. This is 
a useful technique for the analysis of biological molecules 
but has two limitations. Firstly the crystallisation of the 
matrix and the sample on the plates results in a non homo-
geneous surface which leads to loss of resolution and sec-
ondly most sample preparations are carried out in an acidic 
environment where metal and/or protein complexes tend to 
dissociate. In view of these limitations we have used a liq-
uid matrix approach [25] in order to perform the study at 
physiological pH values and to maintain the homogeneity 
of the sample. Furthermore as signal suppression is com-
mon in MALDI analysis, we omitted the use of an internal 
standard and the first measurement was carried out using 
the peptide with no added copper.
By preparing a 1:1 molar ratio of peptide and CuII at pH 
7.0, it is possible to monitor the dissociation of CuII from 
the peptide as a function of concentration. As the solution 
becomes more dilute, CuII dissociates from the peptide 
complex (Fig. 5); thus at 2 μmol/L (Fig. 5a) the domi-
nant species is the 1:1 peptide- CuII complex; at 63 nmol/L 
(Fig. 5b) the relative size of the free peptide peak increases; 
at 31 nmol/L (Fig. 5c), the free peptide peak dominates 
and at 16 nmol/L (Fig. 5d) there is virtually no detectable 
peptide CuII complex. From this data we estimate an affin-
ity constant for CuII and the N-terminal model peptide of 
50–60 nmol/L (log K1 = 8.7–8.8). At the highest copper-
peptide concentration (2 μmol/L) there was also a minor 
contribution in the MS associated with a two CuII/peptide 
species. Spectrophotometric titration of DTHFPIAIF-NH2 
with CuII resulted with an identical affinity constant namely 
log K1 = 8.8 (supplementary Figure S7 and Table S1).
Fig. 4  Fluorescence titration of M21K-TMR-hepcidin with CuII. 
a M21K-TMR-hepcidin (0.5 µmol/L) in MOPS (0.25 mol/L, pH 
7.45): acetonitrile (50:50) was quenched by the addition of CuIISO4 
(2 µmol/L) in 50 µL aliquots; b Analysis of the same titration, moni-
toring the fluorescence at 578 nm
 J Biol Inorg Chem
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A similar mass spectra series was obtained with CuII/hep-
cidin (Fig. 6). At 510 nmol/L the peak heights of hepcidin and 
the CuII/hepcidin complex are similar (Fig. 6a), at 128 nmol/L 
the hepcidin peak height is marginally larger (Fig. 6b) and 
at 32 nmol/L the hepcidin peak height dominates the spec-
tra (Fig. 6d). From these spectra we estimate the CuII affin-
ity constant of hepcidin to fall in the range 500–600 nmol/L 
(log K1 = 7.7–7.8); an order of magnitude lower than that 
of the N-terminal peptide. As with the N-terminal peptide, a 
two CuII/hepcidin species was also detected at the higher pep-
tide concentrations. Similar results were also obtained from 
K21(Cl2CF)-Hepcidin-Cu
II (supplementary Figure S7).
In summary log CuII affinity constants for the two fluo-
rescently labelled hepcidins were 7.5 and 7.2 and the log 
CuII affinity constant for native hepcidin determined by 
mass spectrometry was 7.7–7.8. These values suggest that 
the presence of the fluorescent probe only slightly reduces 
the affinity for CuII. Significantly the log CuII affinity con-
stant for labelled N-terminal nonapeptide bound to CuII is 
approximately tenfold tighter than the hepcidin molecule, 
again confirming the difficulty of using short peptides to 
model cations binding to polypeptides.
We conclude that native hepcidin binds CuII with a log 
K1 value of 7.7–7.8. This value agrees with the previous 
estimate of Tselepis et al. [8] (Log K1 ≫ 6) and is now 
sufficiently accurate to undertake speciation studies with 
potential endogenous CuII chelators, for instance albumin.
Discussion
Hepcidin binds CuII with relatively high affinity (Log 
K1 = 7.7), but is this value sufficiently high to compete with 
intracellular copper chaperone proteins and extracellular pro-
teins, for instance albumin? The intracellular labile copper 
pool is vanishingly small (<femtomolar) [26] due to the neces-
sity of preventing copper from competing with iron and man-
ganese for enzyme active sites [27]. At such low CuII concen-
trations, hepcidin will not be able to bind copper. In contrast 
the extracellular concentration of labile CuII is much higher, 
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typically 1–2 μmol/L [28], and the majority of this pool is 
bound to albumin. The affinity of human serum albumin for 
CuII is logK1 = 12 [21] which is approximately 100,000 times 
higher than the value for hepcidin as reported in this study. As 
CuII is kinetically labile [13], it is expected to rapidly distrib-
ute between albumin and hepcidin. The serum albumin con-
centration is approximately 600 µmol/L, whereas that of hep-
cidin is of the order of 10 nmol/L. Thus the bulk of kinetically 
labile CuII, will be bound to albumin. It is estimated that the 
concentration of hepcidin coordinated to CuII in normal serum 
is <1 fmol/L. Thus under both intracellular and extracellular 
environments, hepcidin will be unable to compete with other 
endogenous CuII binding ligands and thus it is unlikely that the 
binding of copper to hepcidin plays a role in iron homeostasis.
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